Anxiety and sleep disorders

Anxiety disorders are widespread among patients of primary care physicians and are the cause of increased morbidity and access to healthcare. Anxiety is a reaction of the body to the effects of stress and is manifested by the development of psychovegetative syndrome. In the general population, 5 to 7% of people have clinically significant anxiety, and in the practice of primary care physicians, these disorders are detected in every fourth patient. Anxiety disorder contributes to the development of psychogenic somatic pathology and/or negatively affects the course of background disease. Most patients with anxiety disorders suffer from various sleep disorders. In general practice, the frequency of sleep disorders reaches 73%. Chronic sleep disorder can act as a stressor that contributes to the development of pathophysiological changes in the body and increases anxiety. The above determines the need for early detection of sleep disorders and its timely treatment. The current treatment strategy for patients with sleep disorders involves an individualized approach to insomnia therapy. The existing arsenal of drugs used to treat sleep disorders allows this principle to be applied taking into account concomitant diseases (including anxiety disorders). The choice of product is also determined by good tolerability, efficacy and high safety profile. The optimal drug that answers the above requirements is doxylamine succinate, which allows you to effectively stop both anxiety symptoms and sleep disorders. Due to its high safety profile, doxylamine succinate can be used in the treatment of insomnia in pregnant women. The release form determines the convenience of use and the possibility of selecting an individual dose of the drug.